PMID- 19181757
OWN - NLM
STAT- MEDLINE
DCOM- 20090519
LR  - 20090202
IS  - 0267-6591 (Print)
IS  - 0267-6591 (Linking)
VI  - 23
IP  - 4
DP  - 2008 Jul
TI  - The effect of daily administration of IL-18 on cardiac structure and function.
PG  - 237-42
LID - 10.1177/0267659108101511 [doi]
AB  - Recently, the cytokine Interleukin-18 (IL-18) has been shown to be increased as a 
      result of cardiac surgery. Elevated IL-18 has been associated with neurological 
      dysfunction, systemic inflammatory response syndrome (SIRS), and multiple organ 
      dysfunction syndrome (MODS) post open-heart surgery. The intent of the study 
      contained herein was to determine the effect of IL-18 administration on cardiac 
      function and structure. Eight C57BL/6 female mice were treated daily with 
      0.5microg/mouse of recombinant IL-18 for 7 days. Long axis echocardiography 
      (ECHO) measurements of the anatomical and hemodynamic function of the heart for 
      all mice were studied 24h after the last dose. The left ventricular wet weights 
      increased from 84 +/- 1 to 93 +/- 3 mg when comparing the placebo (n = 8) with 
      the IL-18 groups, respectively (p = 0.01). With ECHO analysis, IL-18 
      significantly increased left ventricular (LV) mass, the left atrium dimensions 
      (LA), and the left ventricular posterior wall thickness (LVPW) over the 8-day 
      time period (p < 0.01). There was a 5-fold increase in interstitial cardiac 
      collagen content and a 30% increase in myocyte size in the IL-18 compared with 
      the control groups (p < 0.01). Administration of IL-18 appears to induce 
      interstitial fibrosis and myocyte hypertrophy, resulting in increased ventricular 
      stiffness. Thus, increased IL-18 during and post open-heart surgical procedures 
      may induce left ventricular diastolic dysfunction and affect post-operative 
      outcomes.
FAU - Platis, A
AU  - Platis A
AD  - Circulatory Sciences Graduate Perfusion Program, College of Medicine, The 
      University of Arizona, Tucson, AZ, USA.
FAU - Yu, Q
AU  - Yu Q
FAU - Moore, D
AU  - Moore D
FAU - Khojeini, Ev
AU  - Khojeini E
FAU - Tsau, P
AU  - Tsau P
FAU - Larson, Df
AU  - Larson D
LA  - eng
GR  - R01 HL079206-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Perfusion
JT  - Perfusion
JID - 8700166
RN  - 0 (Interleukin-18)
SB  - IM
MH  - Animals
MH  - Cardiac Output/*drug effects
MH  - Cardiomegaly/chemically induced
MH  - Echocardiography
MH  - Female
MH  - Fibrosis/chemically induced
MH  - Heart/*drug effects/*physiopathology
MH  - Interleukin-18/*pharmacology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Myocytes, Cardiac/drug effects
MH  - Ventricular Dysfunction, Left/*chemically induced
EDAT- 2009/02/03 09:00
MHDA- 2009/05/20 09:00
CRDT- 2009/02/03 09:00
PHST- 2009/02/03 09:00 [entrez]
PHST- 2009/02/03 09:00 [pubmed]
PHST- 2009/05/20 09:00 [medline]
AID - 23/4/237 [pii]
AID - 10.1177/0267659108101511 [doi]
PST - ppublish
SO  - Perfusion. 2008 Jul;23(4):237-42. doi: 10.1177/0267659108101511.